Using CRISPR/Cas9 screening, researchers found that loss of ABCC1 strongly increased the sensitivity of AML cells to Venetoclax. Genetic and pharmacologic ABCC1 inactivation potentiated the anti-leukemic effects of BCL-2 inhibitors and efficiently re-sensitized Venetoclax-resistant leukemia cells.
[Nature Communications]

Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News